Skip to main content
Fig. 2 | Advances in Rheumatology

Fig. 2

From: Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

Fig. 2

Influence of baseline disease activity and body weight on response to secukinumab. a) Differences in median changes (+ interquartile range) of DAS28-CRP and ASDAS-CRP at 8, 24 and 52 weeks between patients with the highest vs. lower disease activity scores at baseline. **P < 0.01, ***P < 0.001, ****P < 0.0001. b) Significant correlations between baseline disease activity and disease activity score changes at the various time points (Note: events in the fourth graph appear to be fewer than the number of patients analyzed due to overlapping dots). c) Differences in median changes (+ interquartile range) of DAS28-CRP and ASDAS-CRP at 8, 24 and 52 weeks between patients with body weights above and below median values. *P < 0.05.

Back to article page